# Intra-Cellular Fundamentals

ITCI | Stock | ## USD 51.42 0.68 1.34% |

Intra-Cellular Ther fundamentals help investors to digest information that contributes to Intra-Cellular Ther's financial success or failures. It also enables traders to predict the movement of Intra-Cellular Stock. The fundamental analysis module provides a way to measure Intra-Cellular Ther's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intra-Cellular Ther stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Intra-Cellular | Select Account or Indicator |

**M**, while Consolidated Income is projected to decrease to (291.6

**M**).

## Intra-Cellular Working Capital Analysis

Intra-Cellular Ther's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .## Intra-Cellular Ther Working Capital | ## 379.9 Million |

Working Capital | = | Current Assets | - | Current Liabilities |

## Current Intra-Cellular Ther Working Capital | 401.13 M |

Most of Intra-Cellular Ther's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra-Cellular Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Intra-Cellular Working Capital Historical Pattern

Today, most investors in Intra-Cellular Ther Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intra-Cellular Ther's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's working capital growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Intra-Cellular Ther working capital as a starting point in their analysis.

Intra-Cellular Ther Working Capital |

Share

Timeline |

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Compare to competition |

## Intra-Cellular Capital Expenditure

## Capital Expenditure | ## (351,454) |

According to the company's disclosures, Intra-Cellular Ther has a Working Capital of 401.13

**M**. This is 5.76% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturersâ€”Specialty & Generic industry. The working capital for all United States stocks is 72.86% higher than that of the company.## Intra-Cellular Ther Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Intra-Cellular Ther's current stock value. Our valuation model uses many indicators to compare Intra-Cellular Ther value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intra-Cellular Ther competition to find correlations between indicators driving Intra-Cellular Ther's intrinsic value. More Info.Intra-Cellular Ther is considered the number one company in current valuation category among related companies. It is currently regarded as number one stock in current liabilities category among related companies creating about 0.03 of Current Liabilities per Current Valuation. The ratio of Current Valuation to Current Liabilities for Intra-Cellular Ther is roughly 30.99 . Intra-Cellular Ther Current Liabilities is most likely to increase significantly in the upcoming years. The last year's value of Current Liabilities was reported at 53.36 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Intra-Cellular Ther by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Intra-Cellular Ther's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intra-Cellular Ther's earnings, one of the primary drivers of an investment's value.## Intra-Cellular Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra-Cellular Ther's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra-Cellular Ther could also be used in its relative valuation, which is a method of valuing Intra-Cellular Ther by comparing valuation metrics of similar companies.Intra-Cellular Ther is currently under evaluation in retained earnings category among related companies.

## Intra-Cellular Ther Current Valuation Drivers

We derive many important indicators used in calculating different scores of Intra-Cellular Ther from analyzing Intra-Cellular Ther's financial statements. These drivers represent accounts that assess Intra-Cellular Ther's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intra-Cellular Ther's important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (2 M) | (2.13 M) | (447.64 K) | (591.09 K) | (554.93 K) | (598.74 K) | |

Revenue Per Employee | 7.85 K | 5.02 K | 184 | 59.4 K | 163.68 K | 176.6 K | |

Average Assets | 381.88 M | 400.13 M | 296.14 M | 602.7 M | 586.77 M | 498.29 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (98.62 M) | (154.76 M) | (147.24 M) | (226.46 M) | (283.59 M) | (291.05 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (98.62 M) | (154.76 M) | (147.24 M) | (226.46 M) | (283.59 M) | (291.05 M) | |

Earnings before Tax | (98.83 M) | (155.13 M) | (147.72 M) | (226.99 M) | (284.12 M) | (291.6 M) | |

Average Equity | 366.64 M | 371.23 M | 241.82 M | 544.06 M | 517.6 M | 443.81 M | |

Enterprise Value | 737.94 M | 553.56 M | 1.82 B | 2.28 B | 4.18 B | 4.51 B | |

Free Cash Flow | (81.22 M) | (118.56 M) | (128.68 M) | (230.34 M) | (259.87 M) | (266.71 M) | |

Invested Capital | 419.49 M | 265.96 M | 130.47 M | 648.16 M | 368.21 M | 332.89 M | |

Invested Capital Average | 333.71 M | 306.89 M | 193.88 M | 423.85 M | 451.48 M | 372.11 M | |

Market Capitalization | 790.28 M | 623.33 M | 1.9 B | 2.55 B | 4.26 B | 4.6 B | |

Tangible Asset Value | 471.49 M | 357.21 M | 251.19 M | 717.31 M | 489.92 M | 435.39 M | |

Working Capital | 455.01 M | 319.14 M | 194.1 M | 654.05 M | 413.92 M | 379.9 M |

## Intra-Cellular Fundamentals

Return On Equity | (43.21) % | |||

Return On Asset | (24.72) % | |||

Profit Margin | (294.89) % | |||

Operating Margin | (296.47) % | |||

Current Valuation | 4.36 B | |||

Shares Outstanding | 81.46 M | |||

Shares Owned by Insiders | 2.43 % | |||

Shares Owned by Institutions | 91.82 % | |||

Number of Shares Shorted | 3.71 M | |||

Price to Earning | (6.56) X | |||

Price to Book | 8.96 X | |||

Price to Sales | 42.40 X | |||

Revenue | 102.92 M | |||

Gross Profit | (13.08 M) | |||

EBITDA | (304.55 M) | |||

Net Income | (303.5 M) | |||

Cash and Equivalents | 771.85 M | |||

Cash per Share | 8.18 X | |||

Total Debt | 24.39 M | |||

Debt to Equity | 0.03 % | |||

Current Ratio | 14.36 X | |||

Book Value Per Share | 5.98 X | |||

Cash Flow from Operations | (294.63 M) | |||

Short Ratio | 4.79 X | |||

Earnings Per Share | (3.20) X | |||

Price to Earnings To Growth | (0.08) X | |||

Number of Employees | 512 | |||

Beta | 1.24 | |||

Market Capitalization | 4.36 B | |||

Total Asset | 542.57 M | |||

Retained Earnings | (728.79 M) | |||

Working Capital | 401.13 M | |||

Current Asset | 541.82 M | |||

Current Liabilities | 140.69 M |

## About Intra-Cellular Ther Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra-Cellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra-Cellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra-Cellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Deferred Revenue | 1.5 M | 1.8 M | |

Cost of Revenue | 8 M | 7.1 M | |

Revenues | 83.8 M | 90.4 M | |

Revenue to Assets | 0.17 | 0.17 | |

Revenue Per Employee | 163.7 K | 176.6 K |

## Intra-Cellular Ther Investors Sentiment

The influence of Intra-Cellular Ther's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intra-Cellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Investor biases related to Intra-Cellular Ther's public news can be used to forecast risks associated with investment in Intra-Cellular. The trend in average sentiment can be used to explain how an investor holding Intra-Cellular can time the market purely based on public headlines and social activities around Intra-Cellular Ther. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.

Intra-Cellular Ther's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intra-Cellular Ther's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intra-Cellular Ther's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Intra-Cellular Ther.

## Intra-Cellular Ther Implied Volatility | 101.56 |

Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Altman Z Score analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

## Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.

Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | Go | |

Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | Go | |

Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges | Go | |

Bond DirectoryFind actively traded corporate debentures issued by US companies | Go | |

Fund ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges | Go | |

Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities | Go | |

Global CorrelationsFind global opportunities by holding instruments from different markets | Go | |

Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | Go |

Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 4.9 B | Quarterly Revenue Growth YOY 1.77 | Return On Assets -0.28 | Return On Equity -0.5 |

The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.